WHY COMPREHENSIVE GENOMIC PROFILING?
Single gene tests target single hotspot events, like BRAF V600E mutation, or involvement in a translocation with often undetermined partner. Unless the specific gene that causes cancer is known, patients usually need to get several single gene tests in order to find therapeutic options.
Hot-spot cancer panels target regions of known cancer genes that have been well-characterized as mutational hot spots. Vast majority of hotspot tests use PCR amplicons technology. Amplicon capture based tests are unable to reliably detect deletions, gene amplifications and translocations. Hot-spot analysis misses up to 20% of clinically important mutations in some tumors1. Hot-spots can be extremely sensitive (down to 0.1% at >2000x sequence coverage), however clinical significance of low-level mutations is uncertain.
Unlike single-gene and hot-spot testing, comprehensive genomic profiling evaluates most cancer-related genes in a single test in the most accurate and cost effective manner.
CANCERPLEX sequences the whole coding region of genes, detecting less common alterations of the direct drug targets. CancerPlex matches all functional domains of proteins involved in “drugable” pathways – indirect targets, which dramatically increases the rate of matching patient to therapeutic options. CANCERPLEX is one of the best-in-class sequencing platform with comprehensive gene coverage and high clinical actionability.
- Sorich M, Wiese M, Rowland A, Kichenadasse G, McKinnon R, Karapetis C. Extended RAS Mutations and Anti-EGFR Monoclonal Antibody Survival Benefit in Metastatic Colorectal Cancer: A Meta-Analysis of Randomized, Controlled Trials. Ann Oncol. 2015; 26(1): 13-21.